3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Marijuana Abuse
2
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Pancreatic Cancer Non-resectable
1
Pain
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Marijuana Use
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Interventions
Doxorubicin
16
Zidovudine
13
Vincristine
12
Bleomycin
11
Interferon alpha-2
6
Cyclophosphamide
6
Methotrexate
5
Liposomes
5
Leucovorin
5
Dexamethasone
5
tecogalan
4
sargramostim
4
Filgrastim
4
Etoposide
4
Cytarabine
4
Ritonavir
3
Nivolumab
3
Fluorouracil
3
pomalidomide
2
liposomal doxorubicin
2
interferon alfa-n1
2
Watchful Waiting
2
Valganciclovir
2
Tumor Necrosis Factor-alpha
2
Tobacco Use Cessation Devices
2
Thalidomide
2
Surveys and Questionnaires
2
Rituximab
2
Paclitaxel
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Acquired Immunodeficiency Syndrome
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled